Previous 10 | Next 10 |
A New Pipeline Product Has Been Added. Lineage Cell announced that it has added a new program in auditory neuronal cell transplants for the treatment of hearing loss. The new development program will treat disorders in which the ear can detect sound, but the transmission of impulses to the bra...
Expansion of Pipeline Into a Third Neuronal Cell Type Builds on Existing Capabilities Intellectual Property Has Been Filed Covering Composition and Methods for Generating Auditory Neuronal Progenitors Hearing Loss Afflicts More Than 5% of the Population; More Than 43...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that full results from a Phase 1/2a clinical study of RG6501 ( OpRegen ® ), a retinal pig...
Full Year Financials In Line With Expectations. Lineage Cell reported a 4Q21 loss of $28.2 million or $(0.17) per share, and a loss of $43.0 million or $(0.26) per share for FY21. The larger than expected loss in 4Q21 was due to the accrual of $20.6 million for future obligations payable to it...
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2021 Results Conference Call March 10, 2022 04:30 PM ET Company Participants Ioana Hone - Head, IR Brian Culley - CEO Kevin Cook - CFO Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants Kristen Kluska - Cantor Fitzgerald Joe P...
Lineage Cell Therapeutics press release (NYSE:LCTX): Q4 GAAP EPS of -$0.17 misses by $0.12. Revenue of $1.2M (+200.0% Y/Y) beats by $0.56M. Cash and cash equivalents totaled $55.7 million as of December 31, 2021. For further details see: Lineage Cell Therapeutics GAAP EPS of -$0.17 miss...
Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Development and Commercialization of RG6501 (OpRegen ® ) in Transaction Worth up to $670 Million Retinal Tissue Restoration and Visual Improvements Reported in Four ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday,...
Fireside Chat with B. Riley Research Scheduled for 2:00pm Eastern Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Li...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright Bioconnect Virtua...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...